3 Stocks I Saw on T...
Health Care: Drugs
Celldex Therapeutics Inc. (CLDX: NASDAQ)
$4.08 0.09 | 2.26%
06/04/12 - 04:00 PM ET
Ratio Comparisons
| Company | Industry | S&P 500 | |
| Valuation Ratios | |||
|---|---|---|---|
| P/E Ratio (TTM) | n.a. | 173.50 | 17.70 |
| P/E High - Last 5 Yrs | n.a. | n.a. | 67.70 |
| P/E Low - Last 5 Yrs | n.a. | n.a. | 12.50 |
| Beta | 1.74 | 0.96 | 0.98 |
| Price to Sales (TTM) | 25.52 | 4.16 | 1.42 |
| Price to Book (MRQ) | 2.17 | 3.92 | 2.41 |
| Price to Tangible Book (MRQ) | 3.15 | 5.44 | 5.08 |
| Price to Cash Flow (TTM) | -5.20 | 46.50 | 9.80 |
| Price to Free Cash Flow (TTM) | -5.80 | -315.20 | 17.40 |
| Dividends | |||
| Dividend Yield (%) | 0.00 | 0.30 | 2.10 |
| Dividend Yield - 5 Yr Avg (%) | n.a. | 0.30 | 2.20 |
| Dividend 5 Yr Growth Rate (%) | n.a. | 35.82 | -0.76 |
| Payout Ratio (TTM) | 0.00 | 63.00 | 30.00 |
| Sales (MRQ) vs Qtr 1 Yr Ago (%) | -3.30 | 6.80 | 11.80 |
| Sales (TTM) vs TTM 1 Yr Ago (%) | -80.20 | -3.40 | 9.20 |
| Growth Rates (%) | |||
| Sales - 5 Yr Growth Rate (%) | 38.96 | 0.00 | 1.79 |
| EPS (MRQ) vs Qtr 1 Yr Ago (%) | n.a. | -93.00 | 17.50 |
| EPS (TTM) vs TTM 1 Yr Ago (%) | n.a. | -93.00 | 17.50 |
| EPS - 5 Yr Growth Rate (%) | n.a. | n.a. | -1.66 |
| Capital Spending - 5 Yr Growth Rate (%) | n.a. | -9.04 | -1.17 |
| Financial Strength | |||
| Quick Ratio (MRQ) | 7.40 | 2.90 | 1.10 |
| Current Ratio (MRQ) | 7.50 | 3.60 | 1.60 |
| LT Debt to Equity (MRQ) | 0.09 | 0.04 | 0.82 |
| Total Debt to Equity (MRQ) | 0.14 | 0.09 | 0.96 |
| Interest Coverage (TTM) | n.a. | 22.20 | 5.50 |
| Profitability Ratios (%) | |||
| Gross Margin (TTM) | 20.20 | 62.80 | 46.90 |
| Gross Margin - 5 Yr Avg | 78.40 | 63.90 | 47.70 |
| EBITD Margin (TTM) | n.a. | 15.20 | 18.90 |
| EBITD - 5 Yr Avg | -193.79 | 0.00 | 0.00 |
| Pre-Tax Margin (TTM) | n.a. | 8.80 | 12.10 |
| Pre-Tax Margin - 5 Yr Avg | n.a. | -0.50 | 10.30 |
| Management Effectiveness (%) | |||
| Net Profit Margin (TTM) | -5.26 | 0.03 | 0.09 |
| Net Profit Margin - 5 Yr Avg | n.a. | -6.20 | 7.00 |
| Return on Assets (TTM) | -35.30 | 1.90 | 3.10 |
| Return on Assets - 5 Yr Avg | -33.60 | -4.20 | 2.50 |
| Return on Investment (TTM) | -41.00 | 2.40 | 7.90 |
| Return on Investment - 5 Yr Avg | -60.80 | -5.80 | 6.50 |
| Efficiency | |||
| Revenue/Employee (TTM) | 89,146.00 | 229,628.00 | 449,376.00 |
| Net Income/Employee (TTM) | -468,505.00 | 6,227.00 | 39,003.00 |
| Receivable Turnover (TTM) | 47.90 | 7.10 | 7.60 |
| Inventory Turnover (TTM) | n.a. | 3.00 | 8.30 |
| Asset Turnover (TTM) | 0.10 | 0.70 | 0.40 |
Portfolios with CLDX
- Portfolio NameUser Type
- Userbio
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- Contributor7 Cancer Drug Stocks to Kno...
- ContributorStocks Under-$10 Moving Hig...
- Contributor10 Cheap Biotech Stocks Tha...
- User3rdwavemedia Portfolio 1
- UserSUPRATRADE 7 Top Stocks for...
- UserASCO 2010
- UserSolstock
Latest CLDX Headlines from TheStreet
- ASCO '12 Stocks: Winners and Losers 06.04.12 | 06:06 am
- Biotech Stock Mailbag: ASCO, Celldex, Obesity Drug Game-Changer 05.25.12 | 05:05 am
- Celldex Targeted Drug Shrinks Breast Cancer 05.23.12 | 04:05 pm
- The Next Big Thing In Biotech: Celldex
05.18.12 | 07:05 am - 7 Stocks Under $10 Making Big Moves 05.17.12 | 12:05 pm
- Biotech Stock Live Chat Recap: ASCO & Obesity 05.17.12 | 11:05 am
- Celldex Screw-Up Nixes ASCO Data Slot 05.01.12 | 07:05 am
- Biotech Stock Mailbag: All You Need to Know About Hep C Drugs 04.13.12 | 05:04 am
- 8 Stocks Under $10 Moving Higher 03.20.12 | 12:03 pm
- Biotech Stock Chat: Recap 03.15.12 | 11:03 am
Press Releases for CLDX
- Celldex Therapeutics To Present At The Jefferies 2012 Global Healthcare Conference - Business Wire 05.31.12 | 09:05 am
- Celldex’s CDX-011 Demonstrates High Response Rates In Patients With Metastatic Breast Cancer Expressing Elevated Levels Of GPNMB And In Triple Negative Disease - Business Wire 05.23.12 | 04:05 pm
- Celldex Therapeutics To Host Call To Announce Topline Results From The EMERGE Study In Advanced Breast Cancer - Business Wire 05.18.12 | 10:05 am
- Celldex Reports First Quarter 2012 Financial Results - Business Wire 05.03.12 | 08:05 am
- Celldex Announces Plans To Release Topline Results From The EMERGE Study In Advanced Breast Cancer - Business Wire 05.01.12 | 07:05 am
- Celldex Announces Exercise Of Over-Allotment Option - Business Wire 03.14.12 | 05:03 pm
- Celldex Reports Fourth Quarter And Fiscal 2011 Financial Results - Business Wire 03.07.12 | 07:03 am
- Celldex Therapeutics To Host Corporate 2011 Year-End And 2012 Objectives Update Call - Business Wire 02.29.12 | 03:02 pm
- Celldex Therapeutics To Present At The Citi 2012 Global Health Care Conference - Business Wire 02.24.12 | 10:02 am
- Celldex Prices Public Offering Of Common Stock - Business Wire 02.24.12 | 09:02 am
Partner Headlines for CLDX
- IsoRay: A Potential Small-Cap Bio-Pharma Multi-Bagger - Seeking Alpha 05.29.12 | 09:05 am
- Pre-Market Most Active for May 24, 2012 : BAC, PPL, EMC, NTAP, HPQ, MTGE, CLDX, TS, FB, MT, QQQ, VOD - NASDAQ 05.24.12 | 12:05 pm
- Analyst Insights: Celldex, InterMune, American Tower, Thermo Fisher, Jiayuan.com May 24th - Wall St. Cheat Sheet 05.24.12 | 11:05 am
- After Hours Most Active for May 23, 2012 : NTAP, HPQ, BAC, BLK, IFSIA, QQQ, F, CLDX, KMI, PFE, ERIC, FB - NASDAQ 05.23.12 | 08:05 pm
- Breast Cancer Immunotherapy: A New Hope In The Fight - Seeking Alpha 03.09.12 | 08:03 am
- Notable Put Options Activity in Celldex Therapeutics - Benzinga 03.06.12 | 01:03 pm
- Notable Put Options Activity in Celldex Therapeutics - Benzinga 02.27.12 | 01:02 pm
- Immunocellular Again Pushing To $2 - Seeking Alpha 02.15.12 | 09:02 am
- 10 Biotech Stocks With 100% Upside In 2012: Part One - Seeking Alpha 02.09.12 | 10:02 am
- Biotech Stocks To Watch In 2012 - Seeking Alpha 02.06.12 | 09:02 am
